Suppr超能文献

人血浆中染色体外环状DNA上单核苷酸KRAS突变的纯化与检测方法。

Methods for the purification and detection of single nucleotide KRAS mutations on extrachromosomal circular DNA in human plasma.

作者信息

Bøllehuus Hansen Lasse, Jakobsen Sandra Fugl, Zole Egija, Noer Julie Boertmann, Fang Li Tai, Alizadeh Sefa, Johansen Julia Sidenius, Mohiyuddin Marghoob, Regenberg Birgitte

机构信息

Department of Biology, University of Copenhagen, Copenhagen, Denmark.

Roche Sequencing Solutions, Belmont, California, USA.

出版信息

Cancer Med. 2023 Sep;12(17):17679-17691. doi: 10.1002/cam4.6385. Epub 2023 Aug 21.

Abstract

BACKGROUNDS

Despite recent advances, many cancers are still detected too late for curative treatment. There is, therefore, a need for the development of new diagnostic methods and biomarkers. One approach may arise from the detection of extrachromosomal circular DNA (eccDNA), which is part of cell-free DNA in human plasma.

AIMS

First, we assessed and compared two methods for the purification of eccDNA from plasma. Second, we tested for an easy diagnostic application of eccDNA liquid biopsy-based assays.

MATERIALS & METHODS: For the comparison we tested a solid-phase silica purification method and a phenol/chloroform method with salt precipitation. For the diagnostic application of eccDNA we developed and tested a qPCR primer-based SNP detection system, for the detection of two well-established cancer-causing KRAS mutations (G12V and G12R) on circular DNA. This investigation was supported by purifying, sequencing, and analysing clinical plasma samples for eccDNAs containing KRAS mutant alleles in 0.5 mL plasma from 16 pancreatic ductal adenocarcinoma patients and 19 healthy controls.

RESULTS

In our method comparison we observed, that following exonuclease treatment a lower eccDNA yield was found for the phenol/chloroform method (15.7%-26.7%) compared with the solid-phase purification approach (47.8%-65.9%). For the diagnostic application of eccDNA tests, the sensitivity of the tested qPCR assay only reached ~10 in a background of 10 wild type (wt) KRAS circular entities, which was not improved by general amplification or primer-based inhibition of wt KRAS amplification. Furthermore, we did not detect eccDNA containing KRAS in any of the clinical samples.

DISCUSSION

A potential explanation for our inability to detect any KRAS mutations in the clinical samples may be related to the general low abundance of eccDNA in plasma.

CONCLUSION

Taken together our results provide a benchmark for eccDNA purification methods while raising the question of what is required for the optimal fast and sensitive detection of SNP mutations on eccDNA with greater sensitivity than primer-based qPCR detection.

摘要

背景

尽管最近取得了进展,但许多癌症在发现时已为时过晚,无法进行根治性治疗。因此,需要开发新的诊断方法和生物标志物。一种方法可能来自于对染色体外环状DNA(eccDNA)的检测,它是人类血浆中游离DNA的一部分。

目的

第一,我们评估并比较了两种从血浆中纯化eccDNA的方法。第二,我们测试了基于eccDNA液体活检检测的简易诊断应用。

材料与方法

为了进行比较,我们测试了固相二氧化硅纯化方法和苯酚/氯仿加盐沉淀法。对于eccDNA的诊断应用,我们开发并测试了一种基于qPCR引物的SNP检测系统,用于检测环状DNA上两个公认的致癌KRAS突变(G12V和G12R)。通过纯化、测序和分析16例胰腺导管腺癌患者和19例健康对照者0.5 mL血浆中含有KRAS突变等位基因的eccDNA的临床血浆样本,支持了本研究。

结果

在我们的方法比较中,我们观察到,在外切核酸酶处理后,苯酚/氯仿法的eccDNA产量(15.7%-26.7%)低于固相纯化方法(47.8%-65.9%)。对于eccDNA检测的诊断应用,在10个野生型(wt)KRAS环状实体的背景下,所测试的qPCR检测的灵敏度仅达到约10,通过一般扩增或基于引物的wt KRAS扩增抑制并未提高该灵敏度。此外,我们在任何临床样本中均未检测到含有KRAS的eccDNA。

讨论

我们无法在临床样本中检测到任何KRAS突变的一个可能解释可能与血浆中eccDNA的总体低丰度有关。

结论

综上所述,我们的结果为eccDNA纯化方法提供了一个基准,同时提出了一个问题,即比基于引物的qPCR检测具有更高灵敏度的eccDNA上SNP突变的最佳快速灵敏检测需要什么条件。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf80/10523981/1d58273237a0/CAM4-12-17679-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验